Radioiodination of balsalazide, bioevaluation, and characterization as a highly selective radiotracer for imaging of ulcerative colitis in mice

J Labelled Comp Radiopharm. 2022 Mar;65(3):71-82. doi: 10.1002/jlcr.3961. Epub 2022 Jan 17.

Abstract

This work focuses on tracking ulcerative colitis in mice. High labeling yield and radiochemical purity were achieved for the formation of a [125/131 I]balsalazide radiotracer at optimum conditions of oxidizing agent content (chloramines-T [Ch-T], 75 μg), substrate amount (100 μg), pH of reaction mixture (6), reaction time (30 min), and temperature (37°C), using radioactive iodine-125 (200-450 MBq). The radiolabeled compound, [125/131 I]balsalazide, was stable in serum and saline solution during 24 h. Balsalazide is acting as a peroxisome proliferator-activated receptor (PPARγ). Biodistribution studies were carried in normal and ulcerated colon mice. High uptake of 75 ± 1.90% injected dose/g organ (ID/g) observed in ulcerated mice confirmed the suitability of [131 I]balsalazide as a novel radiotracer for ulcerative colitis imaging in mice.

Keywords: PPARγ receptor; balsalazide; biological evaluation; radioiodination; ulcerative colitis.

MeSH terms

  • Animals
  • Colitis, Ulcerative* / diagnostic imaging
  • Iodine Radioisotopes / chemistry
  • Mesalamine
  • Mice
  • Phenylhydrazines
  • Thyroid Neoplasms*
  • Tissue Distribution

Substances

  • Iodine Radioisotopes
  • Phenylhydrazines
  • Mesalamine
  • balsalazide